Trials / Completed
CompletedNCT02108288
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-1085EL ophthalmic solution | |
| DRUG | Carteolol long-acting ophthalmic solution | |
| DRUG | Latanoprost ophthalmic solution |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-05-01
- Completion
- 2014-08-01
- First posted
- 2014-04-09
- Last updated
- 2015-04-22
- Results posted
- 2015-04-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02108288. Inclusion in this directory is not an endorsement.